Universal Ibogaine Inc. (IBOGF) Stock Analysis

Universal Ibogaine Inc. (IBOGF) Healthcare & Pipeline Overview

Universal Ibogaine Inc. is a Canadian life sciences company specializing in addiction treatment clinics and the clinical research of ibogaine as a therapeutic for addiction. With a focus on addressing the opioid crisis, the company operates within the biotechnology sector, seeking innovative solutions for addiction management.

What Is the Investment Thesis for IBOGF?

Universal Ibogaine Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its focus on ibogaine-based addiction treatment. The company's planned clinical trials represent a key catalyst, with positive results potentially leading to increased investor interest and future revenue streams. However, the company's negative P/E ratio of -4.16 and negative profit margin of -34.6% indicate financial challenges. The high beta of 4.61 suggests significant volatility. Success hinges on navigating regulatory hurdles, securing funding for research and operations, and demonstrating the efficacy and safety of ibogaine treatment. The stock currently offers no dividend yield.

Based on FMP financials and quantitative analysis

IBOGF Key Highlights

Market Cap of $0.00B indicates a micro-cap company with limited resources and higher risk.

• P/E Ratio of -4.16 reflects negative earnings, suggesting the company is not currently profitable.
• Profit Margin of -34.6% highlights significant operational inefficiencies and cost management challenges.
• Gross Margin of 9.0% indicates a limited ability to generate profit from sales after accounting for the cost of goods sold.
• Beta of 4.61 suggests the stock is significantly more volatile than the market average, indicating higher risk.

Who Are IBOGF's Competitors?

IBOGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IBOGF's Key Strengths?

Focus on ibogaine-based therapy.

• Planned clinical trials for addiction treatment.
• Established presence in the Canadian addiction treatment market.

What Are IBOGF's Weaknesses?

Negative P/E ratio and profit margin.

• High beta indicates significant volatility.
• Reliance on a single therapeutic compound (ibogaine).

What Could Drive IBOGF Stock Higher?

Planned clinical trials for ibogaine-based addiction treatment.

• Expansion of addiction treatment clinic network in Canada.
• Research and development of new ibogaine-based therapies.

What Are the Key Risks for IBOGF?

Financial-distress signal — its Altman Z-Score of -9.33 sits in the distress zone (elevated bankruptcy risk).

• Regulatory hurdles for ibogaine treatment.
• Competition from established addiction treatment providers.
• Negative public perception of ibogaine.
• Financial challenges due to negative P/E ratio and profit margin.
• High stock volatility due to high beta.

What Are the Growth Opportunities for IBOGF?

• Expansion of Clinic Network: Universal Ibogaine can expand its network of addiction treatment clinics across Canada and potentially into other countries. The increasing demand for addiction treatment services, driven by the opioid crisis, creates a favorable environment for growth. Establishing new clinics in underserved areas can increase patient access and revenue. The timeline for expansion depends on securing funding and obtaining necessary regulatory approvals. The market size for addiction treatment services is estimated to be billions of dollars annually.
• Clinical Trial Success and Regulatory Approval: The successful completion of clinical trials for ibogaine-based therapy could lead to regulatory approval by health authorities. This would allow Universal Ibogaine to market its treatment as a recognized and evidence-based solution for addiction. Regulatory approval would significantly enhance the company's credibility and market position. The timeline for regulatory approval depends on the progress of clinical trials and the review process of regulatory agencies. The market for approved addiction treatment medications is substantial.
• Partnerships with Healthcare Providers: Collaborating with hospitals, rehabilitation centers, and other healthcare providers can expand Universal Ibogaine's reach and referral network. Forming strategic partnerships can increase patient referrals and integrate ibogaine therapy into mainstream healthcare settings. These partnerships can also provide access to additional resources and expertise. The timeline for establishing partnerships depends on negotiations and agreements with potential partners. The market for healthcare partnerships is significant.
• Development of New Ibogaine-Based Therapies: Universal Ibogaine can invest in research and development to create new ibogaine-based therapies for different types of addiction and mental health disorders. Expanding the therapeutic applications of ibogaine can broaden the company's target market and revenue potential. This requires ongoing research and clinical trials. The timeline for developing new therapies depends on the complexity of the research and regulatory requirements. The market for new therapies is substantial.
• International Expansion: Universal Ibogaine can expand its operations beyond Canada and establish treatment clinics in other countries with high rates of addiction. Entering new markets can significantly increase the company's revenue and global presence. This requires careful planning, market research, and regulatory compliance. The timeline for international expansion depends on the specific target markets and regulatory environments. The global market for addiction treatment is vast.

What Are IBOGF's Competitive Advantages?

• Focus on ibogaine-based therapy differentiates it from competitors.
• Proprietary knowledge and expertise in ibogaine treatment.
• Established network of addiction treatment clinics in Canada.

What Does IBOGF Do?

Universal Ibogaine Inc. is a life sciences company dedicated to developing and operating addiction treatment clinics across Canada. Founded with the mission to combat the growing addiction crisis, particularly the opioid epidemic, the company is exploring innovative treatment methods centered around ibogaine, a naturally occurring psychoactive substance. Ibogaine has shown promise in interrupting addictive behaviors and reducing withdrawal symptoms. The company's core business involves establishing and managing specialized addiction treatment centers that provide a holistic approach to recovery. These clinics offer a range of services, including medical supervision, psychological counseling, and aftercare support. Universal Ibogaine aims to create a safe and supportive environment for individuals seeking to overcome addiction. In addition to its clinic operations, Universal Ibogaine is actively engaged in clinical research to investigate the efficacy and safety of ibogaine-based therapies for addiction treatment. The company is planning clinical trials to gather scientific evidence and potentially pave the way for regulatory approval of ibogaine as a recognized treatment option. The company is headquartered in Calgary, Canada.

What Products and Services Does IBOGF Offer?

• Develops addiction treatment clinics in Canada.
• Acquires existing addiction treatment clinics.
• Operates addiction treatment clinics.
• Conducts clinical trials for ibogaine-based addiction treatment.
• Researches the use of ibogaine for addiction therapy.
• Provides a holistic approach to addiction recovery.

How Does IBOGF Make Money?

• Generates revenue from operating addiction treatment clinics.
• Provides medical supervision and psychological counseling services.
• Conducts clinical trials and seeks regulatory approval for ibogaine-based therapies.

What Industry Does IBOGF Operate In?

Universal Ibogaine operates within the biotechnology sector, specifically targeting the addiction treatment market. The demand for effective addiction therapies is growing due to the ongoing opioid crisis and increasing rates of substance abuse. The competitive landscape includes pharmaceutical companies developing traditional addiction medications and other biotechnology firms exploring alternative treatments. Universal Ibogaine's focus on ibogaine-based therapy differentiates it from competitors, but also introduces regulatory and acceptance challenges.

Who Are IBOGF's Key Customers?

• Individuals seeking treatment for addiction.
• Patients struggling with opioid addiction.
• Healthcare providers referring patients to addiction treatment clinics.

Universal Ibogaine Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -9.33 places it in the distress zone, a signal of elevated financial risk.

Quarterly Financial Performance: Universal Ibogaine Inc.

Revenue for Universal Ibogaine Inc. came in at $505K during Q3 FY2025, a 88.6% improvement versus the preceding quarter. The company recorded a net loss of $48K, with diluted EPS of $-0.00.

Key Financial Metrics

Return on assets is -9.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.39 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -24.0%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Universal Ibogaine Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Nicholas Peter Karos. IBOGF has traded publicly since 2022.

IBOGF Financials

IBOGF Latest News

No recent news available for IBOGF.

IBOGF Analyst Consensus

IBOGF MoonshotScore

What Investors Ask About Universal Ibogaine Inc. (IBOGF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources